BioNTech plans to amend Phase 3 ROSETTA Breast-01 to test pumitamig with Gilead's Trodelvy instead of chemotherapy; the change needs regulatory approval.
Western Digital rose 3.9% Wednesday as BofA raised its target to $800 and Morgan Stanley cut to $643, both keeping bullish ...
Bernstein analyst James Hooper reaffirmed a Buy rating on BASF on Tuesday, holding his price target at 61 euros. The ...
About 2,000 trade unionists rallied in Strasbourg against the EU Inc draft, demanding binding guarantees for workers' rights as a committee vote slipped to 5 November.
Moderna shares have been on a tear, and the reasons behind that run are worth separating into what has already happened and ...
BP shares sit 1.4% below their 52-week high after a 3.65% Friday gain, as Q3 refining margins nearly doubled and net debt is ...
Plug Power's stock closed Monday at 1.23 euros, hovering just above its 52-week low of 1.21 euros — a valuation that says more about the market's mood on hydrog ...
Ocugen confirmed 140 patients enrolled in the liMeliGhT Phase 3 trial of OCU400, with the primary endpoint now measured using ...
Lenzing's fully guaranteed EUR 300 million rights issue is set to close on 20 October, but Berenberg's downgrade highlights ...
IonQ shares climbed 8.7% in yesterday's session, riding a rebound across quantum computing names that followed a selloff ...
TSMC has attached a firm condition to any further American manufacturing footprint: whoever builds the chips, TSMC runs the ...
Caterpillar pledged up to $10M for North Carolina workforce training, kept its $1.63 dividend, and faces a margin test in Oct ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results